Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

AI-ECHO Hemodynamic Phenotyping in Septic Shock

2 de noviembre de 2026 actualizado por: Second Affiliated Hospital of Guangzhou Medical University

AI-ECHO-Based Intelligent Hemodynamic Subtyping and Dynamic Evolution in Septic Shock: A Prospective Observational Cohort Study

This is a prospective, single-center, observational cohort study. The purpose of this study is to investigate the hemodynamic heterogeneity and dynamic evolution patterns in patients with septic shock, using point-of-care echocardiography combined with artificial intelligence technology. The study will enroll 240 adult patients with septic shock admitted to the ICU. Standardized cardiac ultrasound examinations will be performed at multiple time points, and multi-dimensional clinical-echocardiographic data will be collected. An AI-based automatic echocardiographic analysis system will be developed, and unsupervised machine learning will be applied to identify distinct hemodynamic subtypes and their dynamic evolution trajectories. This study aims to provide innovative solutions for individualized and precise hemodynamic management of septic shock.

Descripción general del estudio

Estado

Aún no reclutando

Intervención / Tratamiento

Descripción detallada

Background

Septic shock is the most severe stage of sepsis and is associated with mortality as high as 40%-50%. Its pathophysiological core involves profound hemodynamic disturbances resulting from complex interactions among abnormal vascular tone, relative or absolute intravascular volume deficiency, myocardial depression, and microcirculatory dysfunction.

Accumulating evidence has demonstrated substantial heterogeneity in hemodynamic profiles among patients with septic shock, including hyperdynamic states, left ventricular systolic or diastolic dysfunction, right ventricular dysfunction, and various combined phenotypes. The traditional binary classification of "warm shock" versus "cold shock" is too simplistic to capture this complexity. Such heterogeneity may partly explain why uniform treatment strategies, such as early goal-directed therapy, have yielded inconsistent results and may cause iatrogenic harm in certain subgroups.

Echocardiography has become an important tool for hemodynamic assessment in the intensive care unit (ICU). It enables noninvasive, real-time evaluation of cardiac structure and function, including left ventricular ejection fraction (LVEF), global longitudinal strain (GLS), right ventricular function, diastolic function, cardiac output, and volume status. However, its clinical utility is limited by:

  • High operator dependency and interobserver variability;
  • Time-consuming post-processing and interpretation;
  • Difficulty in performing frequent dynamic assessments in busy ICU settings; and
  • Limited integrated analysis of multiple parameters over time.

Recent advances in artificial intelligence (AI), particularly deep learning, have shown considerable promise in medical image analysis. In echocardiography, AI has demonstrated promising performance in view classification, cardiac structure segmentation, and automated measurement of functional parameters. Meanwhile, unsupervised machine learning methods provide potential approaches for identifying disease subtypes from high-dimensional clinical data.

Building on the established "Guangzhou Sepsis Cohort" and prior research experience in AI-assisted critical care medicine, this study will integrate AI and echocardiography to systematically characterize hemodynamic phenotypes and their dynamic evolution in patients with septic shock.

Study Design

This is a prospective, single-center, observational cohort study. A total of 360 adults with septic shock admitted to the ICU of The Second Affiliated Hospital of Guangzhou Medical University are anticipated to be consecutively enrolled.

Echocardiographic examinations will be performed on Day 1, Day 3, and Day 7 after enrollment. Clinical data, laboratory measurements, treatment information, and clinical outcomes will be collected according to the study protocol.

At each echocardiographic time point, standardized point-of-care echocardiography will be performed using the same model of ultrasound system and a phased-array transducer. Cine loops of the apical four-chamber, two-chamber, and three-chamber views will be acquired for at least three cardiac cycles. Additional Doppler, M-mode, right ventricular-focused, left ventricular outflow tract, and inferior vena cava recordings will be acquired as required for the prespecified echocardiographic measurements and as detailed in the imaging manual. All images will be stored in de-identified DICOM format using a unique study identification code.

AI-derived measurements will be used for research purposes only and will not guide clinical management. Clinical treatment will be determined by the treating clinical team and will not be assigned by the study.

Clinical data collected at or near the echocardiographic examinations will include vital signs, laboratory measurements, fluid balance, vasopressor dosage, and other treatment information. Blood samples will be collected on Day 1, Day 3, and Day 7 for targeted proteomic and metabolomic analyses, as specified in the study protocol.

Study Objectives

Primary Objective:

To identify and characterize distinct hemodynamic subtypes of septic shock using an unsupervised Gaussian mixture model based on prespecified multidimensional echocardiographic parameters.

Secondary Objectives:

• Longitudinal changes and dynamic evolution of hemodynamic status within 7 days after enrollment;

  • Associations of hemodynamic phenotypes with clinical severity and clinical outcomes;
  • Agreement between AI-derived and blinded expert echocardiographic measurements;
  • Exploratory associations of targeted proteomic and metabolomic profiles with hemodynamic phenotypes; and
  • Exploratory development and internal validation of an early-warning model for 28-day all-cause mortality.

Study Population

Adults (≥18 years) with septic shock, diagnosed according to the Sepsis-3 criteria, who meet the eligibility criteria listed in the Eligibility section will be consecutively enrolled from the ICU of The Second Affiliated Hospital of Guangzhou Medical University. Eligible participants must have an expected ICU stay of at least 72 hours, and written informed consent must be obtained from the patient or a legally authorized representative.

Outcome Measures

Primary Outcome:

Hemodynamic subtypes identified using an unsupervised Gaussian mixture model based on prespecified multidimensional echocardiographic parameters collected within 7 days after enrollment.

Secondary Outcomes:

  • Agreement between AI-derived echocardiographic measurements and blinded expert reference measurements, evaluated using intraclass correlation coefficients and Bland-Altman analyses;
  • Associations between hemodynamic subtypes and 28-day mortality;
  • Associations between hemodynamic subtypes and organ failure severity, as assessed by the Sequential Organ Failure Assessment (SOFA) score;
  • Duration of vasopressor use; and
  • ICU and hospital lengths of stay.

Statistical Analysis

Sample Size Considerations: The planned enrollment of 240 participants is based on the anticipated number of eligible septic shock admissions during the recruitment period, expected consent and follow-up completion, and study feasibility. The target sample size is intended to provide an adequate dataset for exploratory hemodynamic phenotyping and longitudinal echocardiographic analyses. As the primary objective is exploratory hemodynamic phenotyping using unsupervised analysis, no formal hypothesis-based power calculation was performed. Analyses of clinical outcomes, multi-omics profiles, and early-warning models will be considered exploratory, and model complexity will be limited according to the effective sample size and number of observed events.

Continuous variables will be summarized as mean ± standard deviation or median with interquartile range, as appropriate. Categorical variables will be summarized as frequencies and percentages.

An unsupervised Gaussian mixture model will be applied to identify hemodynamic subtypes based on prespecified echocardiographic parameters. Clinical characteristics, treatment information, and outcomes will be compared among the identified subtypes.

Agreement between AI-derived measurements and blinded expert reference measurements will be evaluated using intraclass correlation coefficients and Bland-Altman analyses. Targeted proteomic and metabolomic analyses will evaluate associations between protein or metabolite abundances and hemodynamic phenotype membership using methods appropriate for high-dimensional data. Where applicable, the false discovery rate will be used to account for multiple comparisons. These analyses will be considered exploratory.

An exploratory early-warning model for 28-day all-cause mortality will be developed using prespecified candidate predictors. Model discrimination will be assessed using the area under the receiver operating characteristic curve, and calibration will be evaluated using calibration plots and calibration statistics. Internal validation will be performed using bootstrap resampling or cross-validation. The number of candidate predictors and model complexity will be limited according to the number of observed events to reduce the risk of overfitting.

Multivariable logistic regression or Cox proportional hazards models will be constructed, as appropriate, to explore factors associated with adverse clinical outcomes. Repeated measurements and missing data will be addressed according to the prespecified statistical analysis plan.

Statistical analyses will be performed using SPSS, R, and Python. A two-sided P value <0.05 will be considered statistically significant, with exploratory analyses interpreted accordingly.

Tipo de estudio

De observación

Inscripción (Estimado)

240

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Weiyan Chen, MD, PhD
  • Número de teléfono: +86 13751845652
  • Correo electrónico: sam11124@163.com

Copia de seguridad de contactos de estudio

  • Nombre: Lili Tao, MD
  • Número de teléfono: +86 020-34153246
  • Correo electrónico: taollicu@163.com

Ubicaciones de estudio

    • Guangdong
      • Guangzhou, Guangdong, Porcelana, 511436
        • The Second Affiliated Hospital of Guangzhou Medical University
        • Contacto:
          • Weiyan Chen, MD, PhD
          • Número de teléfono: +86 13751845652
          • Correo electrónico: sam11124@163.com
        • Contacto:
          • Lili, Tao
          • Número de teléfono: +86 020-34153246
          • Correo electrónico: taollicu@163.com
        • Investigador principal:
          • Weiyan Chen, MD, PhD
        • Sub-Investigador:
          • Lili Tao, MD
        • Sub-Investigador:
          • Sihong Xie, PhD

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Método de muestreo

Muestra no probabilística

Población de estudio

This is a prospective observational cohort study enrolling adult patients with septic shock admitted to the ICU. The study aims to construct a multi-dimensional clinical-echocardiographic database, develop an AI-based automatic echocardiographic analysis system, identify hemodynamic subtypes using unsupervised machine learning, and reveal the dynamic evolution patterns of hemodynamics in septic shock.

Descripción

Inclusion Criteria:

  1. Age ≥18 years.
  2. Confirmed diagnosis of septic shock according to the Sepsis-3 criteria.
  3. Expected ICU stay of at least 72 hours.
  4. Written informed consent obtained from the patient or legally authorized representative.

Exclusion Criteria:

Patients meeting any of the following criteria will be excluded:

  1. Severe chronic heart disease, such as severe valvular heart disease or chronic heart failure with left ventricular ejection fraction (LVEF) <30%.
  2. Acute coronary syndrome.
  3. Status post cardiac surgery.
  4. Pregnancy.
  5. Inability to obtain high-quality echocardiographic images at screening.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Modelos observacionales: COHORT
  • Perspectivas temporales: PROSPECTIVE

Cohortes e Intervenciones

Grupo / Cohorte
Intervención / Tratamiento
Septic Shock Patients

Adults with septic shock admitted to the intensive care unit who meet the eligibility criteria listed in the Eligibility section. Participants will undergo standardized point-of-care echocardiography on Day 1, Day 3, and Day 7 after enrollment, together with clinical data and blood sample collection as specified in the study protocol. Clinical management will be determined by the treating clinical team and will not be assigned by the study. AI-derived echocardiographic measurements will be used for research purposes only and will not guide clinical management.

Standardized point-of-care echocardiography will be performed on Day 1, Day 3, and Day 7 after enrollment. Images will be acquired according to the imaging manual and stored in de-identified DICOM format using a unique study identification code. Echocardiographic parameters will be used for hemodynamic phenotyping and assessment of changes over time.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Echocardiography-Derived Hemodynamic Phenotypes in Adults With Septic Shock
Periodo de tiempo: Within 7 days after enrollment

Identification and characterization of distinct hemodynamic phenotypes in adults with septic shock using unsupervised analysis of prespecified multidimensional echocardiographic parameters. The parameters may include measures of left ventricular systolic and diastolic function, right ventricular function, cardiac output or flow, and inferior vena cava dynamics, depending on data availability and image quality. The number and characteristics of the identified phenotypes will be determined using prespecified model selection and evaluation procedures.

Within 7 days after enrollment

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Longitudinal Changes and Dynamic Evolution of Hemodynamic Status
Periodo de tiempo: Day 1, Day 3, and Day 7 after enrollment.

Serial changes in echocardiographic parameters and transitions among hemodynamic phenotypes will be evaluated during follow-up.

Day 1, Day 3, and Day 7 after enrollment.
Associations Between Hemodynamic Phenotypes and Clinical Severity and Outcomes
Periodo de tiempo: Within 7 days after enrollment for severity measures; up to 28 days or during the index hospitalization for clinical outcomes.

Associations of hemodynamic phenotypes with SOFA score, blood lactate, 28-day all-cause mortality, vasopressor duration, and ICU and hospital length of stay will be evaluated.

Within 7 days after enrollment for severity measures; up to 28 days or during the index hospitalization for clinical outcomes.
Agreement Between AI-Derived and Blinded Expert Echocardiographic Measurements
Periodo de tiempo: Day 1, Day 3, and Day 7 after enrollment.

Agreement for prespecified echocardiographic parameters will be evaluated using intraclass correlation coefficients and Bland-Altman analyses.

Day 1, Day 3, and Day 7 after enrollment.
Associations Between Molecular Profiles and Hemodynamic Phenotypes
Periodo de tiempo: Day 1, Day 3, and Day 7 after enrollment.

Exploratory associations of targeted proteomic and metabolomic profiles with hemodynamic phenotypes will be evaluated.

Day 1, Day 3, and Day 7 after enrollment.
Exploratory Early-Warning Model for 28-Day All-Cause Mortality
Periodo de tiempo: Predictors within 7 days; mortality through 28 days after enrollment.

An exploratory model will be developed and internally validated using clinical and echocardiographic data.

Predictors within 7 days; mortality through 28 days after enrollment.

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Weiyan Chen, MD, PhD, Second Affiliated Hospital of Guangzhou Medical University

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

30 de noviembre de 2026

Finalización primaria (Estimado)

9 de noviembre de 2028

Finalización del estudio (Estimado)

30 de noviembre de 2028

Fechas de registro del estudio

Enviado por primera vez

25 de octubre de 2026

Primero enviado que cumplió con los criterios de control de calidad

2 de noviembre de 2026

Publicado por primera vez (Actual)

9 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

9 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

2 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir